As the U.S. market experiences a slight downturn following a six-day winning streak for the S&P 500, investors are keenly observing small-cap stocks, which can often offer unique opportunities amid broader market fluctuations. In this environment, identifying promising small-cap companies requires looking beyond immediate headlines to uncover those with solid fundamentals and growth potential, such as Viemed Healthcare and other undiscovered gems in the sector.
Top 10 Undiscovered Gems With Strong Fundamentals In The United States
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Oakworth Capital | 42.08% | 15.43% | 7.31% | ★★★★★★ |
| Central Bancompany | 32.38% | 5.41% | 6.60% | ★★★★★★ |
| FineMark Holdings | 122.25% | 2.34% | -25.87% | ★★★★★★ |
| FRMO | 0.09% | 44.64% | 49.91% | ★★★★★☆ |
| Valhi | 43.01% | 1.55% | -2.64% | ★★★★★☆ |
| Pure Cycle | 5.11% | 1.07% | -4.05% | ★★★★★☆ |
| Gulf Island Fabrication | 19.65% | -2.17% | 42.26% | ★★★★★☆ |
| Reitar Logtech Holdings | 31.39% | 231.46% | 41.38% | ★★★★☆☆ |
| Solesence | 82.42% | 23.41% | -1.04% | ★★★★☆☆ |
| Qudian | 6.38% | -68.48% | -57.47% | ★★★★☆☆ |
Underneath we present a selection of stocks filtered out by our screen.
Viemed Healthcare (NasdaqCM:VMD)
Simply Wall St Value Rating: ★★★★★★
Overview: Viemed Healthcare, Inc. operates in the United States offering home medical equipment and post-acute respiratory healthcare services, with a market capitalization of $267.18 million.
Operations: The company generates revenue primarily from its Sleep and Respiratory Disorders Sector, amounting to $232.79 million.
Viemed Healthcare seems to be carving a niche in the healthcare sector with its focus on respiratory care and home-based services, aligning well with industry trends. The company reported impressive earnings growth of 19% over the past year, outpacing the broader healthcare industry's 16.8%. Its debt-to-equity ratio has notably improved from 19.4% to 2.9% over five years, reflecting prudent financial management. With EBIT covering interest payments by a healthy margin of 20 times, Viemed's financial health appears robust despite recent insider selling activity. Investors may find potential value here given projected revenue growth and an analyst price target suggesting upside potential from current levels.
Republic Bancorp (NasdaqGS:RBCA.A)
Simply Wall St Value Rating: ★★★★★★
Overview: Republic Bancorp, Inc. operates as a bank holding company for Republic Bank & Trust Company, offering a range of banking products and services in the United States, with a market capitalization of approximately $1.43 billion.
Operations: The company generates revenue primarily from its Core Banking segment, with significant contributions from Republic Processing Group's Credit Solutions and Payment Solutions. The net profit margin is a key financial metric to consider.
Republic Bancorp, with assets totaling US$7.1 billion and equity at US$1 billion, showcases a robust financial position. It has total deposits of US$5.4 billion and loans amounting to US$5.2 billion, supported by a net interest margin of 4.9%. The company maintains an appropriate level of bad loans at 0.4% and holds a sufficient allowance for these at 465%. Earnings surged by 27% last year, outpacing the industry growth rate of 5%, while revenue is projected to grow annually by about 8.66%. Trading below its estimated fair value by roughly 25%, Republic Bancorp appears undervalued in the market landscape.
Crawford (NYSE:CRD.B)
Simply Wall St Value Rating: ★★★★★☆
Overview: Crawford & Company offers claims management and outsourcing solutions for carriers, brokers, and corporations across various regions including the United States, the United Kingdom, Europe, Canada, Australia, Asia, and Latin America with a market capitalization of approximately $551.39 million.
Operations: Crawford & Company generates revenue primarily through four segments: Broadspire ($390.16 million), Platform Solutions ($173.29 million), International Operations ($424.91 million), and North America Loss Adjusting ($314.53 million).
Crawford & Company, a smaller player in the market, has shown promising financial performance recently. The company reported first-quarter 2025 revenue of US$323.34 million, up from US$313.07 million the previous year, with net income rising to US$6.68 million from US$2.84 million year-over-year. Despite its high net debt to equity ratio of 119%, Crawford's earnings growth of 33.7% outpaced the insurance industry average of 5.3%. Furthermore, its price-to-earnings ratio stands at a competitive 17.7x compared to the broader U.S market's 18.1x, suggesting potential value for investors seeking opportunities in this sector.
- Delve into the full analysis health report here for a deeper understanding of Crawford.
Evaluate Crawford's historical performance by accessing our past performance report.
Turning Ideas Into Actions
- Unlock more gems! Our US Undiscovered Gems With Strong Fundamentals screener has unearthed 279 more companies for you to explore.Click here to unveil our expertly curated list of 282 US Undiscovered Gems With Strong Fundamentals.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Crawford might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com